Wave life sciences ltd. (WVE)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14
Cash flows from operating activities
Net loss

-193,638

-146,653

-101,980

-55,660

-19,200

-5,229

Adjustments to reconcile net loss to net cash used in operating activities:
Amortization of lease incentive obligation

-

790

208

-

-

-

Amortization of right-of-use assets

1,613

-

-

-

-

-

Depreciation of property and equipment

7,600

5,600

2,200

784

594

281

Share-based compensation expense

19,509

15,596

12,143

6,847

4,024

-

Net loss on disposal of property and equipment

-

-44

-205

-

-

-14

Deferred rent

-

973

3,594

565

88

-6

Deferred income taxes

-

-

908

-698

36

84

Tax benefit related to share-based compensation

-

-

-

310

-

-

Changes in operating assets and liabilities:
Accounts receivable

-10,000

59,000

1,000

-

-

129

Prepaid expenses

3,665

1,831

3,429

-

-

-

Prepaid expenses and other current assets

-

-

-

1,337

-130

12

Other assets

8,369

8,690

2,431

53

-

-

Accounts payable

-3,497

4,936

3,892

3,369

1,648

9

Accrued expenses and other current liabilities

1,448

5,864

4,550

2,296

267

410

Deferred revenue

-15,983

160,585

-2,893

11,408

-152

152

Operating lease liabilities

-2,816

-

-

-

-

-

Other non-current liabilities

-421

523

823

864

38

-

Net cash used in operating activities

-188,231

-22,862

-83,671

-31,925

-12,527

-4,426

Increase in restricted cash

-

-

-

-

1,055

-

Proceeds from government grant reimbursements for property and equipment

-

-

-

-

3

319

Proceeds from the sale of property and equipment

-

-

-

4

-

14

Purchases of property and equipment

3,918

9,938

18,887

5,567

1,857

590

Net cash used in investing activities

-3,918

-9,938

-18,887

-5,563

-2,909

-257

Cash flows from financing activities
Proceeds from initial public offering, net of offering costs and underwriter commissions

-

-

-

-

101,444

-

Costs associated with initial public offering

-

-

-

1,075

-

-

Proceeds from issuance of Series B preferred shares, net of offering costs

-

-

-

-

62,532

-

Proceeds from government grant

-

-

-

-

112

34

Payments on capital lease obligation

-

16

62

62

126

-

Proceeds from the exercise of share options

2,607

5,110

927

258

-

-

Net cash provided by financing activities

164,399

65,094

94,374

29,121

175,593

5,619

Effect of foreign exchange rates on cash, cash equivalents and restricted cash

114

37

403

-14

15

-327

Net increase (decrease) in cash, cash equivalents and restricted cash

-27,636

32,331

-7,781

-8,381

160,172

609

Deferred offering costs in accounts payable and accrued expenses at period end

-

-

-

-

1,075

72

Cash paid for interest

-

-

-

-

-

86

Equipment acquired for capital lease obligation

-

-

-

-

268

-

Conversion of related party notes payable into ordinary and Series A preferred shares

-

-

-

-

-

9,602

Property and equipment purchases in accounts payable and accrued expenses at period end

-

-

-

-

306

3

At-The-Market Equity Program [Member]
Proceeds from issuance of ordinary shares, net of offering costs

161,792

60,000

93,509

30,000

11,631

5,585